Jatenergy flags higher than expected revenues for Q3
Name: Jatenergy Ltd (ASX:JAT)
Market Capitalisation: $38 million
Closing Share Price: 6.3 cents
Jatenergy (ASX:JAT) is a China-Australia cross-border specialist in Fast Moving Consumer Goods (FMCG) exports. It develops in-house brands for Australian products for sale offline and online, with a focus on milk products and baby formula.
Yesterday it released a market update stating that the September quarter revenues are likely to be materially higher than expected (if the market based its assumptions on income generated in recent quarters). This revolves around the finalisation of the August acquisition of 50% of Sydney-based wholesaler, distributor and exporter, Green Forest International.
Green Forest sells to more than 50 shops and pharmacies in Hong Kong, and over 200 gift shops, duty free stores and daigou (‘personal shopper’) warehouses in Australia, as well as Chinese cross-border platform like Taobao and WeChat.
This represents a significant boost to JAT’s distribution capacity and sales. Based on Green Forest’s earnings, JAT’s revenue for the September quarter is expected to be as much as A$8.7 million.
This estimate includes the impact of Green Forest revenue for only half of the September quarter, and it should be noted that 50% of Green Forest’s contributions are associated with minority interests. The December quarter will benefit from a full three month contribution from Green Forest.
The company’s management noted that sales for the June quarter of A$320,000 were relatively low as the company focused its efforts on putting in place the elements necessary to drive sales, particularly of in-house branded products.
NEURIO, a milk powder that’s sold in supermarkets and baby and maternity stores, is a core in-house brand in the small cap’s control that comes from Sunnya, another of JAT’s acquisitions.
However it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.
JAT to present at Expo
JAT will be showcasing at the inaugural China International Import Expo (CIIE), where Australian businesses are invited to showcase their products and services. Over 500,000 visitors from China and around the world are expected to attend the first expo in November, representing a key opportunity for exposure of JAT’s in-house and client brands.
China is the second largest importer and consumer in the world, and expects to import products and services valued at over US$10 trillion in the next five years. China now takes about two-thirds of Australia’s infant formula exports.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.